News & Updates

Psoriasis ups risk of colorectal cancer
Psoriasis ups risk of colorectal cancer
26 Nov 2021

Patients with psoriasis appear to be at greater risk for developing colorectal cancer, suggests a recent study, noting how gastroenterology consultation and colonoscopic examination are indicated for such individuals presenting with bowel symptoms.

Psoriasis ups risk of colorectal cancer
26 Nov 2021
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021 byKanas Chan

Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.

6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021
Obesity ups risk of early-onset colorectal cancer
Obesity ups risk of early-onset colorectal cancer
22 Nov 2021 byStephen Padilla

Obese people are more likely to develop early-onset colorectal cancer (CRC), suggests a study, noting that the increasing prevalence of obesity in younger generations may significantly contribute to the increase in this disease.

Obesity ups risk of early-onset colorectal cancer
22 Nov 2021
Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
22 Nov 2021 byTristan Manalac

Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
22 Nov 2021
Daratumumab-containing regimens safe, effective against multiple myeloma
Daratumumab-containing regimens safe, effective against multiple myeloma
21 Nov 2021

Adding daratumumab to backbone treatments against multiple myeloma (MM) yields high clinical efficacy and has an acceptable toxicity profile, a recent study has found. Such regimens are good treatment options for newly diagnosed (ND) and relapsed/refractory (RR) MM.

Daratumumab-containing regimens safe, effective against multiple myeloma
21 Nov 2021
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
19 Nov 2021
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
17 Nov 2021

The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.

Statins reduce hepatocellular carcinoma risk in cirrhotic patients
17 Nov 2021